AIM AIM ImmunoTech Inc

Price (delayed)

$2.04

Market cap

$97.56M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.45

Enterprise value

$61.34M

Sector: Healthcare
Industry: Biotechnology

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease ...

Highlights

The debt has dropped by 64% year-on-year and by 2.7% since the previous quarter
AIM ImmunoTech's gross profit has increased by 15% YoY
The company's EPS has shrunk by 132% QoQ but it has surged by 83% YoY
AIM ImmunoTech's gross margin has increased by 27% YoY but it has decreased by 3.1% from the previous quarter
The net income has plunged by 53% YoY and by 25% from the previous quarter
AIM ImmunoTech's quick ratio has decreased by 29% from the previous quarter

Key stats

What are the main financial stats of AIM
Market
Shares outstanding
47.82M
Market cap
$97.56M
Enterprise value
$61.34M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.35
Price to sales (P/S)
398.52
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
376.32
Earnings
Revenue
$163,000
EBIT
-$13.73M
EBITDA
-$13M
Free cash flow
-$10.39M
Per share
EPS
-$0.45
Free cash flow per share
-$0.33
Book value per share
$1.51
Revenue per share
$0.01
TBVPS
$1.98
Balance sheet
Total assets
$64.58M
Total liabilities
$3.29M
Debt
$2.29M
Equity
$61.29M
Working capital
$39.21M
Liquidity
Debt to equity
0.04
Current ratio
36.58
Quick ratio
35.42
Net debt/EBITDA
2.79
Margins
EBITDA margin
-7,972.4%
Gross margin
-394.5%
Net margin
-8,834.4%
Operating margin
-9,295.7%
Efficiency
Return on assets
-26%
Return on equity
-28.2%
Return on invested capital
-62.8%
Return on capital employed
-21.6%
Return on sales
-8,422.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AIM stock price

How has the AIM ImmunoTech stock price performed over time
Intraday
-2.86%
1 week
-5.56%
1 month
-16.39%
1 year
-18.4%
YTD
13.97%
QTD
-10.13%

Financial performance

How have AIM ImmunoTech's revenue and profit performed over time
Revenue
$163,000
Gross profit
-$643,000
Operating income
-$15.15M
Net income
-$14.4M
Gross margin
-394.5%
Net margin
-8,834.4%
The net income has plunged by 53% YoY and by 25% from the previous quarter
The net margin has declined by 32% year-on-year and by 31% since the previous quarter
AIM ImmunoTech's gross margin has increased by 27% YoY but it has decreased by 3.1% from the previous quarter
The operating income has contracted by 22% YoY and by 13% from the previous quarter

Growth

What is AIM ImmunoTech's growth rate over time

Valuation

What is AIM ImmunoTech stock price valuation
P/E
N/A
P/B
1.35
P/S
398.52
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
376.32
The company's EPS has shrunk by 132% QoQ but it has surged by 83% YoY
The P/B is 7% lower than the last 4 quarters average of 1.5 but 7% higher than the 5-year quarterly average of 1.3
AIM's P/S is 199% above its 5-year quarterly average of 137.3 and 12% above its last 4 quarters average of 365.0
AIM ImmunoTech's revenue has increased by 16% YoY but it has decreased by 4.7% QoQ

Efficiency

How efficient is AIM ImmunoTech business performance
The ROE has soared by 72% YoY and by 4.4% from the previous quarter
AIM's ROA is up by 50% YoY
The company's return on sales fell by 31% YoY and by 31% QoQ
The return on invested capital has declined by 22% year-on-year and by 21% since the previous quarter

Dividends

What is AIM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AIM.

Financial health

How did AIM ImmunoTech financials performed over time
The company's total liabilities has shrunk by 55% YoY but it rose by 8% QoQ
AIM ImmunoTech's quick ratio has decreased by 29% from the previous quarter
The debt is 96% smaller than the equity
AIM's debt to equity has dropped by 91% year-on-year
The debt has dropped by 64% year-on-year and by 2.7% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.